Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis

Phase 3 Completed 174 enrolled Hanmi Pharmaceutical Company Limited

RandomizedParallel-groupDouble-blindTreatment

Summary

Efficacy and safety of HCP1102 in patients with perennial allergic rhinitis : A randomized, double-blind, active-controlled, multicenter phase 3 clinical trial

Timeline

Start: 2018-10-23
Primary completion: 2019-06-24
Completion: 2019-06-24

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Levocetrizine	Unknown	—	Oral
Subject	Montelukast	Other / unclassified	—	Oral

Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis

Summary

Timeline

Drugs

Indications